Total: $971.91M | ||||
Company |
Type Of |
Number Of |
Amount |
Investors; Placement Agents; Details |
| | ||||
Arius |
Private placement of stock and warrants |
3.4S and 3.4W |
C$2.55 (US$2) |
Biotechnology Value Fund LP and associated funds bought the shares at C$0.75 each; the two-year warrants are exercisable at the same price (9/28) |
Australian |
Private placement of stock and warrants |
9.485S and 1.654W |
A$3.79 (US$2.63) |
About 60% of the shares were placed with Mercury Investments Ltd., and the remainder were underwritten by Jaguar Advisory Services Pty. Ltd.; they sold at A$0.40 each; the three-year options are exercisable at A$0.60 per share; Hunting Party Securities Ltd. also was a placement agent (9/1) |
Biopure |
Private placement of stock and warrants |
21.37S and 10.69W |
$8.33 |
Biopure sold the Class A shares covered by a shelf registration statement to institutional and individual investors at $0.39 each; the warrants are exercisable at $0.42 per share; C.E. Unterberg, Towbin LLC was placement agent (9/14) |
Bioxel |
Private placement of stock and warrants |
8.04U |
C$3.3 (US$2.53) |
The units, sold at C$0.41 each, consist of one share and a two-year warrant for the purchase of one share at C$0.51; Canaccord Capital Corp. led the deal, and got a two-year warrant to purchase 387,739 shares at C$0.41 each, and a fee of 4.8% of gross proceeds (9/16) |
Corautus |
Private placement of stock and warrants |
0.943S and 0.236W |
$4.93 |
Corautus closed the second tranche of a financing; the first tranche in July involved the same number of shares and warrants on the same terms; the 235,869 warrants are exercisable at a 20% premium at the time of the deal (9/23) |
ChondroGene |
Private placement of stock |
0.526S |
$0.5 |
PowerOne Capital Markets Ltd. placed the shares in Canada at $0.95 each; PowerOne got $30,000 and a warrant to purchase 31,578 shares at the same price (9/13) |
DNAPrint |
Private |
N/A |
$35 |
Dutchess Private Equities Fund committed to purchase $35M in DNAPrint stock over two years, at times and in amounts selected by DNAPrint; Athena Capital Partners arranged the deal (9/28) |
Encysive |
Private placement of stock |
4.6S |
$36.5 |
Encysive sold the shares that were covered under a shelf registration at $7.94 each to Wachovia Securities; the totals include 600,000 shares bought by Wachovia to cover overallotments (9/8) |
Helix BioPharma |
Private placement of stock and warrants |
0.225S and 0.225SW |
C$0.62 (US$0.48) |
Warrants issued in the private placement are exercisable at C$4.50 per share; other details on the financing were not disclosed (9/22) |
Helix |
Private |
2.19S and |
C$4.66 |
The securities were sold to Canadian investors, including Sherfam Inc., the holding company for the Apotex Group of companies; the two and a half year warrants are exercisable at C$3 per share (9/1 and 9/16) |
Human Genome |
Private placement of convertible notes |
N/A |
$250 |
Institutional investors purchased the 2.25% convertible subordinated notes due 2011, which are convertible into common stock at $15.55 per share; they have an option to buy another $50M in notes (9/29) |
INYX Inc. |
Private placement of stock and warrants |
9.19S and 9.19W |
$7.4 |
In one private placement, INYX raised $1.1M from the sale of stock and warrants to institutional investors affiliated with Sands Brothers Inter- national; in a $6.3M financing, INYX paid placement agent Sands Brothers a 10% fee; the five-year warrants carry exercise prices ranging from $1 to $1.11 per share (9/8) |
Medical |
Private |
ND |
$0.5 |
Private investors purchased the restricted stock under undisclosed terms (9/29) |
Myogen Inc. |
Private placement of stock and warrants |
9.2S and 1.8W |
$60 |
The shares were sold at $6.525 each and the warrants are exercisable at $7.80 per share; investors included New Enterprise Associates, InterWest Partners, Perseus-Soros Biopharmaceutical Fund and Sequel Venture Partners; CIBC World Markets and Lazard Freres & Co. LLC were joint placement agents (9/27) |
Nanobac Life |
Private placement of stock |
ND |
$5 |
Nutmeg Group led the financing, which potentially will bring $5M to the company over the next four quarters (9/30) |
NicOx SA (France; Nouveau Marche: NICOX) |
Private placement of stock |
9.44S |
€26 (US$32.2) |
The shares were sold at €2.75 each to 15 European and U.S. institutional investors (9/30) |
Provalis plc |
Private |
33.07S |
£2.6 |
The shares were placed mostly with institutional investors by Evolution Beeson Gregory at 8 pence per share, a discount of about 3% to the previous day's close (9/17) |
Resverlogix |
Private placement of stock |
1.88S |
C$0.4 (US$0.32) |
The shares were sold to a small number of individuals at C$2.15 each; a 7% finder's fee was paid to a third party (9/23) |
Sepracor Inc. |
Private placement of notes |
N/A |
$500 |
The 0% convertible senior subordinated notes due 2024 are convertible into cash plus, under certain circumstances, shares of Sepracor stock at $67.20 per share (9/17) |
YM Biosciences Inc. (Canada; TSE:YM) |
Bought-deal financing |
4.3U |
C$19.8 (US$15.33) |
An underwriting group led by Dundee Securities Corp. and including Canaccord Capital Corp., Sprott Securities, Dlouhy Merchant Group and Haywood Securities bought the units at C$3.15 each; the units consist of one share and half a warrant; each whole warrant is exercisable for three years at C$3.75; the totals include the underwriters' purchase of 2M shares under their option (9/14) |
Notes: | ||||
This chart does not include real estate or manufacturing plant financings. | ||||
# Unless otherwise indicated, shares are traded on the Nasdaq exchange. | ||||
@ Dates refer to the date of the press release. | ||||
Currency conversions are based on exchange rates at the time of the deal. | ||||
N/A = Not applicable; ND = Not disclosed. | ||||
AMEX = American Stock Exchange; ASX = Australian Stock Exchange; LSE = London Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; TSE = Toronto Stock Exchange; VSE = Vancouver Stock Exchange. | ||||
